Xoma Corp (XOMA) Receives a Buy from Wedbush

By Ryan Adsit

Wedbush analyst Liana Moussatos reiterated a Buy rating on Xoma Corp (XOMAResearch Report) today and set a price target of $25. The company’s shares opened today at $18.26.

According to TipRanks.com, Moussatos is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -11.6% and a 29.3% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Aquestive Therapeutics Inc, and Allena Pharmaceuticals Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Xoma Corp with a $27.50 average price target.

See today’s analyst top recommended stocks >>

Based on Xoma Corp’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $1.88 million. In comparison, last year the company had a GAAP net loss of $1.95 million.

Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of XOMA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

XOMA Corp. engages in the discovery and development of innovative therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.